Asthma rescue treatments, time to reboot
- PMID: 32300023
- DOI: 10.1183/13993003.00542-2020
Asthma rescue treatments, time to reboot
Conflict of interest statement
Conflict of interest: J. Charriot has nothing to disclose. Conflict of interest: M. Gaga reports grants from Novartis, Chiesi, Elpen and Menarini, personal fees from BMS and MSD, outside the submitted work. Conflict of interest: C. Suehs has nothing to disclose. Conflict of interest: A. Bourdin has been an investigator in clinical trials for Nuvaira, Pulmonx, Actelion, MSD, United Therapeutic, Vertex, Acceleron and Galapagos, grants and personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis and Sanofi-Regeneron, outside the submitted work.
Comment on
-
Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.Eur Respir J. 2020 Apr 16;55(4):1901872. doi: 10.1183/13993003.01872-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 31949111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical